Porin differentiates TLR mediated proinflammatory response of follicular zone B cell from TLR-unresponsive IL-10 expressing marginal zone B cell

Cytokine

Volumn 76, Issue 2, 2015, Pages 193-205

  Sinha, Debolina ^a   Ghosh, Amlan Kanti ^a   Mukherjee, Subhadeep ^a   Biswas, Ratna ^a   Biswas, Tapas ^a  

^a NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

Author keywords

B 2 cell subsets; Cytokines; Immune regulation; Pattern recognition receptors; Porin

Indexed keywords

BINDING PROTEIN; CD19 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; IMMUNOGLOBULIN; INTERLEUKIN 10; NLR CASPASE RECRUITMENT DOMAIN CONTAINING PROTEIN 5; PATTERN RECOGNITION RECEPTOR; PORIN; TOLL INTERACTING PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; UNCLASSIFIED DRUG; CYTOKINE; DIACYLGLYCEROL; FSL-1 LIPOPROTEIN, SYNTHETIC; IL10 PROTEIN, MOUSE; LIPOPEPTIDE; NLRC5 PROTEIN, MOUSE; OLIGOPEPTIDE; PAM(3)CSK(4) PEPTIDE; SIGNAL PEPTIDE; TOLLIP PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; FEMALE; FOLLICULAR ZONE B CELL; IMMUNOREGULATION; INFLAMMATION; MARGINAL ZONE B CELL; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; UPREGULATION; ANATOMY AND HISTOLOGY; ANIMAL; C57BL MOUSE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; GENETICS; GRAM NEGATIVE BACTERIUM; IMMUNIZATION; IMMUNOLOGY; LYMPHOID TISSUE;

ANIMALS; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; CYTOKINES; DIGLYCERIDES; GRAM-NEGATIVE BACTERIA; IMMUNIZATION; INTERLEUKIN-10; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOPEPTIDES; LYMPHOID TISSUE; MICE, INBRED C57BL; OLIGOPEPTIDES; PLASMA CELLS; PORINS; RECEPTORS, PATTERN RECOGNITION; SPLEEN; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6; UP-REGULATION;

EID: 84943660927     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.07.006     Document Type: Article

References (59)

1. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 2004, 82:488-496.
2. Bekeredjian-Ding I., Jego G. Toll-like receptors-sentries in the B-cell response. Immunology 2009, 128:311-323.
3. Halperin S.A., Dobson S., McNeil S., Langley J.M., Smith B., McCall-Sani R., et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006, 24:20-26.
4. Weeratna R.D., Makinen S.R., McCluskie M.J., Davis H.L. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005, 23:5263-5270.
5. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 2006, 6:823-835.
6. Nikaido H. Porins and specific channels of bacterial outer membranes. Mol. Microbiol. 1992, 6:435-442.
7. Massari P., Visintin A., Gunawardana J., Halmen K.A., King C.A., Golenbock D.T., et al. Meningococcal porin PorB binds to TLR2 and requires TLR1 for signalling. J. Immunol. 2006, 176:2373-2380.
8. Ray A., Chatterjee N.S., Bhattacharya S.K., Biswas T. Porin of Shigella dysenteriae enhances mRNA levels for Toll-like receptor 2 and MyD88, up-regulates CD80 of murine macrophage, and induces the release of interleukin-12. FEMS Immunol. Med. Microbiol. 2003, 39:213-219.
9. Wetzler L.M. Immunopotentiating ability of Neisserial major outer membrane proteins use as an adjuvant for poorly immunogenic substances and potential use in vaccines. Ann. NY Acad. Sci. 1994, 730:367-370.
10. Donnelly J.J., Deck R.R., Liu M.A. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine. J. Immunol. 1990, 145:3071-3079.
11. Lowell G.H., Ballou W.R., Smith L.F., Wirtz R.A., Zotlinger W.D., Hockmeyer W.T. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science 1998, 240:800-802.
12. Ray A., Biswas T. Porin of Shigella dysenteriae enhances Toll-like receptors 2 and 6 of mouse peritoneal B-2 cells and induces the expression of immunoglobulin M, immunoglobulin G2a and immunoglobulin A. Immunology 2005, 114:94-100.
13. Ray A., Karmakar P., Biswas T. Up-regulation of CD80-CD86 and IgA on mouse peritoneal B-1 cells by porin of Shigella dysenteriae is Toll-like receptors 2 and 6 dependent. Mol. Immunol. 2004, 41:1167-1175.
14. Banerjee P., Biswas A., Biswas T. Porin-incorporated liposome induces Toll-like receptors 2- and 6-dependent maturation and type 1 response of dendritic cell. Int. Immunol. 2008, 20:1551-1563.
15. Kantor A.B., Herzenberg L.A. Origin of murine B cell lineages. Annu. Rev. Immunol. 1993, 11:501-508.
16. LeBien T.W., Tedder T.F. B lymphocytes: how they develop and function. Blood 2008, 112:1570-1580.
17. Pasare C., Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 2005, 438:364-368.
18. Elinav E., Strowig T., Henao-Mejia J., Flavell R.A. Regulation of the antimicrobial response by NLR proteins. Immunity 2011, 34:665-679.
19. Rivera A., Chen C.C., Ron N., Dougherty J.P., Ron Y. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int. Immunol. 2001, 13:1583-1593.
20. Borsutzky S., Kretschmer K., Becker P.D., Mühlradt P.F., Kirschning C.J., Weiss S., et al. The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. J. Immunol. 2005, 174:6308-6313.
21. Okada T., Cyster J.G. B cell migration and interactions in the early phase of antibody responses. Curr. Opin. Immunol. 2006, 18:278-285.
22. hi lymphocytes enriched in the splenic marginal zone generate effector cells more rapidly than the bulk of follicular B cells. J. Immunol. 1999, 162:7198-7207.
23. Lund F.E. Cytokine-producing B lymphocytes-key regulators of immunity. Curr. Opin. Immunol. 2008, 20:332-338.
24. Harris D.P., Haynes L., Sayles P.C., Duso D.K., Eaton S.M., Lepak N.M., et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol. 2000, 1:475-482.
25. Mizoguchi A., Bhan A.K. A case for regulatory B cells. J. Immunol. 2006, 176:705-710.
26. Barr T.A., Brown S., Ryan G., Zhao J., Gray D. TLR-mediated stimulation of APC: distinct cytokine responses of B cells and dendritic cells. Eur. J. Immunol. 2007, 37:3040-3053.
27. Roy S., Das A.B., Ghosh A.N., Biswas T. Purification, pore-forming ability, and antigenic relatedness of the major outer membrane protein of Shigella dysenteriae type 1. Infect. Immun. 1994, 62:4333-4338.
28. Nikaido H., Rosenberg E.Y. Porin channels in Escherichia coli: studies with liposomes reconstituted from purified proteins. J. Bacteriol. 1983, 153:241-252.
29. DuBois M., Gilles K.A., Hamilton J.K., Rebers P.A., Smith F. Colorimetric method for determination of sugars and related substances. Anal. Chem. 1956, 28:350-356.
30. Entenman C. Preparation and determination of higher fatty acids. Methods Enzymol. 1957, 3:317.
31. + T cells with porin of Shigella dysenteriae activates the cells toward type 1 polarization. Int. Immunol. 2008, 20:81-88.
32. Biswas A., Meissner T.B., Kawai T., Kobayashi K.S. Cutting edge: impaired MHC class I expression in mice deficient for nlrc5/class I transactivator. J. Immunol. 2012, 189:516-520.
33. van Duin D., Medzhitov R., Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol. 2006, 27:49-55.
34. Cheng C., Jain P., Bettahi I., Pal S., Tifrea D., de la Maza L.M. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors. Vaccine 2011, 29:6641-6649.
35. Kawabe T., Naka T., Yoshida K., Tanaka T., Fujiwara H., Suematsu S., et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994, 1:167-178.
36. Suvas S., Singh V., Sahdev S., Vohra H., Agrewala J.N. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J. Biol. Chem. 2002, 277:7766-7775.
37. Frölich D., Blassfeld D., Reiter K., Giesecke C., Daridon C., Mei H.E., et al. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression. Arthritis Res. Ther. 2012, 14:R54.
38. Mukherjee S., Sinha D., Ghosh A.K., Biswas T. Bacterial ligand stimulates TLR2-dependent chemokines of colon cell. Immunobiology 2014, 219:350-356.
39. Martin F., Kearney J.F. Marginal-zone B cells. Nat. Rev. Immunol. 2002, 2:323-335.
40. Pillai S., Cariappa A., Moran S.T. Marginal zone B cells. Annu. Rev. Immunol. 2005, 23:161-196.
41. Zhang G., Ghosh S. Negative regulation of toll-like receptor-mediated signaling by Tollip. J. Biol. Chem. 2002, 277:7059-7065.
42. Benko S., Magalhaes J.G., Philpott D.J., Girardin S.E. NLRC5 limits the activation of inflammatory pathways. J. Immunol. 2010, 185:1681-1691.
43. Yanaba K., Bouaziz J.D., Matsushita T., Tsubata T., Tedder T.F. The development and function of regulatory B cells expressing IL-10 (B10 Cells) requires antigen receptor diversity and TLR signals. J. Immunol. 2009, 182:7459-7472.
44. Vitale G., Mion F., Pucillo C. Regulatory B cells: evidence, developmental origin and population diversity. Mol. Immunol. 2010, 48:1-8.
45. + phenotype controls T cell-dependent inflammatory responses. Immunity 2008, 28:639-650.
46. Shapiro-Shelef M., Calame K. Regulation of plasma-cell development. Nat. Rev. Immunol. 2005, 5:230-242.
47. Lopes-Carvalho T., Foote J., Kearney J.F. Marginal Zone B cells in lymphocyte activation and regulation. Curr. Opin. Immunol. 2005, 17:244-250.
48. Meyer-Bahlburg A., Bandaranayake A.D., Andrews S.F., Rawlings D.J. Reduced c-myc expression levels limit follicular mature B cell cycling in response to TLR signals. J. Immunol. 2009, 182:4065-4075.
49. Hart G.T., Wang X., Hogquist K.A., Jameson S.C. Krüppel-like factor 2 (KLF2) regulates B-cell reactivity, subset differentiation, and trafficking molecule expression. Proc. Natl. Acad. Sci. USA 2011, 108:716-721.
50. Hoek K.L., Gordy L.E., Collins P.L., Parekh V.V., Aune T.M., Joyce S., et al. Follicular B cell trafficking within the spleen actively restricts humoral immune responses. Immunity 2010, 33:254-265.
51. Treml L.S., Carlesso G., Hoek K.L., Stadanlick J.E., Kambayashi T., Bram R.J., et al. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J. Immunol. 2007, 178:7531-7539.
52. Viau M., Zouali M. B-lymphocytes, innate immunity, and autoimmunity. Clin. Immunol. 2005, 114:17-26.
53. Mariño E., Silveira P.A., Stolp J., Grey S.T. B cell-directed therapies in type 1 diabetes. Trends Immunol. 2011, 32:287-294.
54. Lenert P., Brummel R., Field E.H., Ashman R.F. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J. Clin. Immunol. 2005, 25:29-40.
55. Philpott D.J., Sorbara M.T., Robertson S.J., Croitoru K., Girardin S.E. NOD proteins: regulators of inflammation in health and disease. Nat. Rev. Immunol. 2014, 14:9-23.
56. Tong Y., Cui J., Li Q., Zou J., Wang H.Y., Wang R.F. Enhanced TLR-induced NF-κB signaling and type I interferon responses in NLRC5 deficient mice. Cell Res. 2012, 22:822-835.
57. Yao Y., Qian Y. Expression regulation and function of NLRC5. Protein Cell 2013, 4:168-175.
58. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470:543-547.
59. Maseda D., Smith S.H., DiLillo D.J., Bryant J.M., Candando K.M., Weaver C.T., et al. Regulatory B10 cells differentiate into antibody-secreting cells after transient IL-10 production in vivo. J. Immunol. 2012, 188:1036-1048.